GlassScriptPhysician profile
Marta Mckeague
NPI 1669815627
$3,495.70
in general payments reported to CMS, 2019-2025
22 companies · $965 in 2025
The $965 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $19.40 · 2021: $427 · 2022: $592 · 2023: $320 · 2024: $993 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $645.78 | 2022-2025 | Envista Mx60 Iol, Envista Aspire Iol, Xiidra |
| Tarsus Pharmaceuticals, INC. | $573.55 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $450.60 | 2021-2025 | Acthar |
| Oyster Point Pharma, INC. | $318.68 | 2022-2025 | Tyrvaya |
| Alcon Vision LLC | $278.26 | 2022-2025 | Hydrus Microstent, Simbrinza, Clareon |
| Glaukos Corporation | $230.30 | 2024-2025 | Idosetr, Istent Infinite, Idose |
| Sun Pharmaceutical Industries INC. | $219.12 | 2021-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $119.61 | 2019-2022 | |
| Dompe US, INC. | $102.50 | 2019-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $94.75 | 2019-2021 | |
| Harrow Eye, LLC | $83.87 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $58.66 | 2021 | |
| Allergan, INC. | $53.20 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $52.40 | 2021 | |
| Biotissue Holdings INC. | $49.42 | 2019-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $42.54 | 2023-2024 | Tearcare System, Omni Surgical System |
| Mallinckrodt Enterprises LLC | $28.21 | 2019 | |
| Astellas Pharma US INC | $24.41 | 2024 | Izervay |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Abbvie INC. | $18.58 | 2025 | |
| Amgen INC. | $17.92 | 2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $13.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Mckeague listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.